Introduction AMP-activated protein kinase (AMPK) is a phylogenetically conserved intracellular energy sensor which plays a central role in the regulation of glucose and lipid metabolism [1] . It is a heterotrimeric complex enzyme comprising of a catalytic (a1 or a2), a regulatory (b1 or b2), and an AMP-binding regulatory (c1, c2, or c3)
subunits [1] . AMPK gets activated by alterations in the AMP:ATP ratio in response to energetic stress and requires phosphorylation of Thr 172 in the activation loop of the a catalytic subunit [2] . Once activated, AMPK induces ATP-generating catabolic pathways including glucose and fatty acid oxidation, while inhibiting ATPconsuming anabolic pathways including cholesterol, fatty acid, and triacylglycerol synthesis [1, 3, 2] . Three upstream kinases have been identified as activators of AMPK, the tumor suppressor LKB1, calcium/calmodulin-dependent protein kinase (CaMKK) and TGF-beta-activated kinase-1 (TAK1) [4] [5] [6] .
MS is an inflammatory autoimmune demyelinating disease of CNS, in part, mediated by myelin-specific CD4 T cells [7] . Different classes of immunomodulatory drugs with distinct mechanisms of action have been approved for MS treatment [8] [9] [10] . However, current MS medications are either partially effective with significant side effects or less effective for long term treatment [11, 12] . Therefore, identification of novel targets for developing a new class of drugs is essential, which can be used for MS therapy alone or in combination with existing drugs.
In the present work, we have investigated the status of AMPK in immune cells during EAE disease and its possible role in disease pathology.
Materials and methods
Animals. Female 6-to 8-wk-old C57BL/6 and SJL mice were obtained from National Cancer Institute (NCI), and were housed in pathogen free conditions. The generation of AMPKa1(À/À) and a2(À/À) mice has been described previously [13] [14] [15] . AMPKa1(À/À)(background of C57B6/129), a2(À/À) mice (background of C57B6) and their respective wild type (WT) mice were maintained on a 12:12-h light-dark cycle and received standard rodent chow and water ad libitum. Genotyping was performed by PCR using DNA from a tail-piece as described before [13] [14] [15] . All animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the Medical University of South Carolina, Charleston. Paralyzed mice were afforded facile access to food and water.
Peptide, reagents and cell culture. Myelin proteolipid protein peptide (PLP 139-151 ) (HSLGKWLGHPDKF) and myelin oligodendrocytes protein peptide (MOG 35-55 ) (MEVGWYRSPFSRVVHLYRNGK) were purchased from Peptide International Inc. Louisville, KY USA. The anti-pAMPKa, pACC and AMPKa antibodies were purchased from Cell Signaling. The anti-AMPKa1, b1/2 and -c1 and -c2 Abs were purchased from Epitomics (Burlingame, CA).
EAE induction, Histology and recall response. AMPK null mice (a1
) and respective WT mice (6-8 wk old) were immunized on day 0 and 7 by subcutaneous (s.c.) injections in the flank region with total 100 ll of emulsion containing MOG 35-55 peptide along with killed Mycobacterium tuberculosis H37Ra (400 lg). In case of EAE induction in SJL mice, PLP 139-151 (100 lg/mouse) was used. Each mouse additionally received 200 ng of pertussis toxin (Sigma) by intravenous (i.v.) injection in 300 ll of PBS on day 0 and 7 of immunization and clinical disease was monitored as described earlier [16] . H&E staining of the lumbar region of the spinal cords were performed as described earlier [16] . Myelin MOG 35-55 -immune spleen cells (2 Â 10 5 /100 ll/well) isolated from WT and
AMPKa1
À/À mice were cultured in the presence of MOG (25 lg/ml). Cell proliferation and the production of cytokines (IFNc and IL-17) were examined as before [16] . Separation of subpopulation of T cells. Mice were killed at the peak of EAE disease (day 20) and spleens were removed, the single cell suspension was prepared. Red blood cells (RBC) were lysed by 1Â pharmalyse and then washed twice with RPMI-1640. Finally, the cells were resuspended in RPMI complete media and counted. Total CD3 T cells were enriched using T cells enrichment columns (R&D Systems) as per manufacturer's instructions. Different subpopulation of T cells (CD4, CD8 and CD4CD25) from control and EAE mice were enriched using MagCellect CD4, CD8 and CD4CD25 regulatory T cells isolation kits, respectively (R&D Systems).
Immunoblot analyses. Cells were lysed in lysis buffer [50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 5 mM EDTA, 50 mM NaF, and 0.5% Nonidet P-40] containing a protease inhibitor cocktail (Sigma) and 50 lg of proteins was used for immunoblot analysis of pAMPKa1, pACC, AMPKa, AMPKa1 and b actin using their specific antibodies as described before [16, 17] .
AMPK kinase assay. AMPK activity was assayed by immunoprecipitation followed by kinase assay using recombinant ACC protein (Upstate Biotech) as a substrate as described before [16, 17] .
Nucleotide assay. Adherent, non-adherent and T cells from control and EAE mice were lysed in perchloric acid as described [18] . These extracts were neutralized with 1.5 M KOH/KHCO3 and then separated by high-performance liquid chromatography to measure ATP levels [18] .
Statistical analyses. GraphPad Prism software (GraphPad Software Inc.) was utilized throughout for statistical analysis. Kruskal-Wallis test and Student's t-test were employed to analyze clinical disease score. Statistics for densitometric values comparison for proliferation and cytokine responses were analyzed with one-way multiple-range ANOVA and Student's t-test. A value of p < 0.05 and above was considered significant.
Results and discussion

Expression of AMPK subunits and their isoforms
We first examined the expression of different subunits of AMPK and their isoforms in T cells, antigen presenting cells (macrophages, dendritic and endothelial cells) and mouse brain (Suppl. Fig. S1A ). The expression of a1, b1 and c2 was found to be predominant in all the cells examined; however, expression of a2 was detected only in the brain (Suppl. Fig. S1A ). Since, EAE disease is primarily mediated by T cells, therefore, we examined its expression in freshly isolated subsets of CD3 T cells (CD4, CD8 and CD4CD25) without any stimulation. The expression of a1, b1, c1 and c2 was predominantly expressed in CD4, CD8 and in regulatory (CD4CD25) T cells (Suppl. Fig. S1B ). These results were further supported by quantitative PCR using specific primers of AMPK subunits and their isoforms (Suppl. Fig. S1 C) .
AMPK activity was down regulated during EAE disease progression
To examine the status of AMPK under inflammatory disease condition, we measured AMPK activity and its phosphorylation in CNS at the peak of EAE disease (day 20). AMPK activity was determined by immunoprecipitation with AMPKa antibodies followed by kinase assay using recombinant Acetyl CoA Carboxylase (ACC) as a substrate. AMPK activity was significantly downregulated at the peak of EAE disease in brain compared to control mice (Fig. 1  A) . Similarly, phosphorylation of both AMPK and its bona fide substrate ACC was decreased in lymph nodes under EAE disease (Fig. 1  B) . AMPK activity examined by kinase assay in total spleen cells was also found significantly reduced (Suppl. Fig. S2 ). We further analyzed the expression of AMPK and observed that the protein levels of AMPKa1, -b1/2 and -c1 subunits were all significantly decreased in spleen cells isolated from EAE except -c2 (Fig. 1C) . This data strongly suggests that AMPK activity gets downregulated during EAE disease in lymphoid and non lymphoid organs. Interestingly, the decreased AMPK activity was due to the loss of AMPKa1 and other subunits (b1/2 and c1) at protein levels without any changes in their mRNA expression (Data not shown) suggesting that AMPK is regulated at protein translation step or degradation. This also raises the question about the mechanism of regulation of AMPK protein levels during EAE disease. Whether inflammation is a causative effect or an upstream event in loss of AMPK or vice versa? Recent studies suggest that AMPK and AMPK-related kinases can be regulated by ubiquitin-dependent proteosome degradation [19, 20] , which may be one of the mechanisms of its regulation in immune cells during EAE.
To further investigate whether the inhibition of AMPK activity was confined to in vivo inflammatory condition or it could be mimicked in vitro, a macrophage cell line (Raw 267.4) was used and the inflammatory responses were stimulated with LPS/IFNc (1 lg/ 50 ng/ml) for 18 h followed by examination of phosphorylation of AMPK and ACC. The stimulus with LPS/IFNc downregulated AMPK activity as documented by decreased phosphorylation of AMPKa and ACC (Suppl. Fig. S3Ai ). To mimic EAE disease, we generated Th1 conditioned media from in vitro stimulated CD4 T cells and macrophage cells were treated with Th1 media (1:20 dilution) for 18 h. Interestingly, phosphorylation of AMPKa and ACC was observed very low compared to untreated cells (Suppl. Fig. S3Aii ). Protein levels of AMPK-a1, -b1 and -c1 subunits were slightly decreased in Raw cells treated with LPS/IFNc or Th1 media (Suppl. Fig. 3 Ai&ii). Since microglia are resident APC in the CNS and further activates infiltrated T cells during disease, therefore, we examined AMPK in these cells under inflammatory condition. For this, microglial cell line (BV2) was treated with Th1 conditioned media at different dilutions (from 5 to 100) for 24 h. The phosphorylation of AMPK and ACC was decreased with the increase of Th1 conditioned media (Suppl. Fig. S3B ). Protein levels of AMPK-a1, -b1 and -c1 subunits were not changed in BV2 treated with Th1 conditioned media. These data strongly suggest that AMPK activity is down regulated under in vitro and in vivo inflammatory disease conditions.
AMPK was down regulated in sub-fractions of spleen cells during EAE disease
Spleen cells are comprised of mainly T cells, B cells, macrophages and dendritic cells. Since we observed the downregulation of AMPK in total spleen cells during EAE disease progression, we further examined its activity in subpopulations of spleen cells. For this, we separated spleen cells isolated from control and EAE mice in three different fractions: (1) adherent cells (mainly macrophages); (2) enriched CD3 positive T cells; and (3) non-adherent cells (total lymphocytes). We observed that phosphorylation of ACC and AMPKa was reduced in all fractionated cells isolated from total spleen cells including CD3 T cell, adherent and non-adherent cells as evident from immunoblot analysis of pACC and pAMPKa (Fig. 1D) . We further examined the phosphorylation of ACC and AMPKa in total T cells (CD3) and its subsets (CD4, CD8 and CD4CD25) from control and EAE diseased mice. As depicted in Fig. 1E , we observed the inhibition of phosphorylation of ACC and AMPKa in total T cells (CD3) and their subsets, which was found due to the loss of AMPKa1 protein levels in EAE disease compared to control mice. These results indicate that reduced AMPK activity is a general phenomenon in immune cells during EAE disease process. Our findings are in contrast to others where they have shown the activation of AMPK by antigen receptor and Ca2 + in T lymphocytes mediated by CaMKK [21] . The difference in the outcome of their and our study may be due to the nature of stimulation as they have used PMA/ionomycin or TCR engagement by CD3 ligation (in vitro studies), whereas we have examined the AMPK in immune cells in vivo under disease condition without any in vitro stimulation. Our results have direct relevance to the inflammatory autoimmune disease like EAE/MS and may be implicated to other inflammatory diseases.
A well characterized mechanism of AMPK activity modulation is the alteration of cellular energy levels reflected by an altered AM-P:ATP ratio [1] . Therefore, we investigated the energy status in immune cells under disease by measuring the intracellular ATP and AMP levels in total spleen cells, spleen macrophage and CD3 T cells isolated from control and EAE mice. Higher levels of ATP was detected in total spleen cells (10.3 vs. 6.9 nmol/10 6 cells, P < 0.001) and in spleen macrophage cells (10.8 vs. 5.46 nmol/10 6 cells, P < 0.001), however, no change was found in ATP levels in T cells (7.7 vs. 8.6 nmol/10 6 cells, P < 0.089) isolated from EAE mice compared to the control (Suppl. Fig. S4 ). We were unable to detect AMP levels in total spleen cells, CD3 and spleen macrophage cells suggesting these cells exhibit a normal energy status in EAE mice.
AMPKa1 null mice (À/À) exhibited exacerbated EAE disease severity compared with WT littermates
Since we observed loss of AMPKa1 at protein level in all immune cells, next we examined the effect of AMPKa1 À/À gene disruption on the development of EAE disease using AMPKa1 null mice. EAE was induced in AMPKa1
À/À and WT mice following active immunization with MOG 35-55 . As shown in Fig. 2 and in Table Fig. 1 . AMPK was down regulated at the peak of EAE disease. (A) EAE was induced in C57BL/6 mice using MOG 35-55 peptide and at the peak of disease, mice were killed and AMPK activity was examined in brain homogenate using AMPKa antibody followed by kinase assay as described in methods. 1, the severity of disease was enhanced in AMPKa1 À/À mice (3.37 ± 0.1; p < 0.001) compared with their WT littermates (2.59 ± 0.35) without any change in the onset of the disease ( Table  1 ). The development of severe paralytic symptoms was apparent in AMPKa1 À/À by day 16 with the maximal disease severity score of 3.37 being observed till end of the study (day 26). Although all mice in both groups succumbed to the disease, there was no mortality associated with the acute attack. The hallmark of EAE disease is the infiltration of inflammatory cells into the CNS, leading to tissue damage [22] . Therefore, we examined the status of infiltration of inflammatory cells into the CNS of WT and AMPKa1 À/À mice. As shown in figure 2B , AMPKa1
À/À EAE mice showed profound infiltration of immune cells in the CNS compare to WT mice. We also examined EAE disease induction in AMPKa2 À/À mice and did not observe any significant change in EAE clinical score in AMPKa2
À/ À mice compare with WT mice (Supp. Fig. S5 ), suggesting that a2
isoform does not play role in EAE pathology. Induction of EAE disease predominantly involved the participation of APCs and T cells to induce inflammatory cascade, which express mainly a1. Our novel observations, the loss of AMPKa1 during EAE disease and exacerbation of EAE clinical symptom in AMPKa1 -/-null mice suggesting a critical role of AMPK in the regulation of inflammatory disease progression.
To confirm that AMPKa1 À/À mice were sensitized to MOG 35-55 peptide, we measured the Ag-induced T cell proliferation ex vivo. As shown in Fig. 2C , in vitro culture of spleen cells from WT and AMPKa1 À/À mice showed an antigen-dependent proliferation with no significant change suggesting that the severity of disease in AMPKa1 À/À mice is not due to the higher proliferation of MOGspecific T cell responses. Further, in response to Ag stimulation, spleen cells from WT and AMPKa1 À/À mice induced production of IFNc and IL17 (Fig. 2 D&E) , however, AMPKa1
À/À cells produced higher amount of IFNc with lesser IL17 compare with WT cells. Spleen cells isolated from AMPKa1 À/À mice displayed normal cell proliferation and pro-inflammatory cytokines production suggesting that loss of AMPK did not affect the normal cellular functions which is consistent with a recent report [23] . However, loss of AMPKa1 enhances the production of IFNc with lesser production of IL17 compare with WT mice required further detail study to establish the role of AMPKa1 in modulation of pro-inflammatory cytokines under inflammatory environment. Loss of AMPKa1 expression in all immune cells and the higher production of proinflammatory cytokines during EAE disease indicate an inverse correlation. But, to establish this relationship, enzymatic active AMPKa1 has to be restored in immune cells and examine if levels of cytokines and EAE disease course can be modulated. Altogether, our study identified for the first time that energy sensor is lost during disease in all immune cells and its genetically deficient mice exhibits an increased severity of EAE disease suggesting its critical role in inflammatory disease progression.
